Skip to content
10-K

Annual Report

ENDONOVO THERAPEUTICS, INC. ENDV

0001493152-23-012553

← back to feed
Filed
Apr 17, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Apr 17, 2023 270.29M sh
Operating Cash Flow FY 2022 · Dec 31, 2022 −$678.84K
Operating Cash Flow FY 2022 · Dec 31, 2021 −$986.58K
Long Term Debt FY 2022 · Dec 31, 2022 $7.15M
Stockholders Equity FY 2022 · Dec 31, 2022 −$32.18M
Stockholders Equity FY 2022 · Dec 31, 2021 −$15.77M
Stockholders Equity FY 2022 · Dec 31, 2020 −$14.37M
Current Liabilities FY 2022 · Dec 31, 2022 $33.38M
Current Liabilities FY 2022 · Dec 31, 2021 $17.7M
Total Liabilities FY 2022 · Dec 31, 2022 $33.46M
Total Liabilities FY 2022 · Dec 31, 2021 $17.78M
Current Assets FY 2022 · Dec 31, 2022 $15.82K
Current Assets FY 2022 · Dec 31, 2021 $94.86K
Total Assets FY 2022 · Dec 31, 2022 $1.28M
Total Assets FY 2022 · Dec 31, 2021 $2.01M
Eps Basic FY 2022 · Dec 31, 2022 −$0.13
Eps Basic FY 2022 · Dec 31, 2021 −$0.05
Net Income FY 2022 · Dec 31, 2022 −$18.47M
Net Income FY 2022 · Dec 31, 2021 −$3.1M
Operating Income FY 2022 · Dec 31, 2022 −$3.26M
Operating Income FY 2022 · Dec 31, 2021 −$2.23M
Gross Profit FY 2022 · Dec 31, 2022 $125.37K
Gross Profit FY 2022 · Dec 31, 2021 $58.12K
Cost Of Revenue FY 2022 · Dec 31, 2022 $9.99K
Cost Of Revenue FY 2022 · Dec 31, 2021 $14.99K
Revenue FY 2022 · Dec 31, 2022 $135.36K
Revenue FY 2022 · Dec 31, 2021 $73.11K